Business Wire

ARM

30.11.2022 15:01:36 CET | Business Wire | Press release

Share
Arm Announces Appointment of Paul E. Jacobs and Rosemary Schooler to its Board of Directors

Arm today announced the appointment of new Board members Dr. Paul E. Jacobs, chairman and CEO of XCOM Labs and former CEO and executive chairman of Qualcomm Inc., and Rosemary Schooler, former corporate vice president and general manager of Data Center and AI Sales for Intel. Both bring significant public company experience spanning technology development, business strategy and corporate governance to Arm as it continues to prepare for a public listing.

“The unique insights and depth of experience that Paul and Rosemary bring will help us expand and diversify our Board while providing enormous value to Arm at such a pivotal moment in our journey,” said Rene Haas, CEO, Arm.

Haas added, “Paul has an incredible track record of developing cutting-edge technologies and leading Qualcomm through an amazing growth phase, and Rosemary has demonstrated exceptional leadership capabilities, setting and executing strategic priorities, driving innovation and cultivating customer relationships across a variety of Intel’s businesses during her long career there. I look forward to working with both Paul and Rosemary as we strengthen our leadership position in the semiconductor ecosystem and prepare for the public markets.”

“I have worked with Arm from the early days of smartphones and the wireless internet,” Paul E. Jacobs added. “As computing becomes ever more pervasive, this creates new opportunities to build upon Arm’s market-leading position. I am excited to join Arm’s Board and work with the world-class team here to help drive the next technology revolutions.”

“Arm is poised to be a leader in the semiconductor and computing industries,” said Rosemary Schooler. “Working with customers to solve their most complex technology challenges has been the focus of my career. I’m thrilled to join Arm and look forward to helping the company expand its connected computing footprint across the globe.”

About Paul E. Jacobs

Paul E. Jacobs, Ph.D. is the chairman and CEO of XCOM Labs, which he founded in 2018 to develop high performance wireless technologies and applications. Prior to XCOM, Dr. Jacobs served as CEO and executive chairman of Qualcomm Inc., where he spearheaded the company’s efforts to develop and commercialize fundamental mobile technology breakthroughs that fueled the wireless internet and smartphone revolutions. During his tenure as CEO, Qualcomm’s revenue quadrupled and its market capitalization doubled. Dr. Jacobs is a prolific inventor with over 80 U.S. patents granted or pending in the field of wireless technology and devices.

Dr. Jacobs currently serves as director of Dropbox, Inc. and FIRST. He earned a B.S. in Electrical Engineering and Computer Science, M.S. in Electrical Engineering, and Ph.D. in Electrical Engineering and Computer Science from UC Berkeley. He founded Berkeley’s Jacobs Institute for Design Innovation. Dr. Jacobs is a member of the National Academy of Engineering and a Fellow of the American Academy of Arts and Sciences.

About Rosemary Schooler

Rosemary Schooler is a proven leader with over 30 years of experience in the global technology industry. She most recently served as corporate vice president and general manager of Data Center and AI Sales for Intel Corporation. During her 33-year career at Intel, Ms. Schooler managed and oversaw sales and corporate strategy for the company’s IoT business. She also held vice president and general manager positions at a number of Intel start-up initiatives in the embedded/IoT, networking and storage businesses, including PnL, architecture, product development and customer success efforts. In her networking role, Ms. Schooler led industry transforming initiatives including Network Function Virtualization (NFV) and technologies such as Data Plane Development Kit (DPDK).

Ms. Schooler has supported industry efforts including ATIS and TIA as well as non-profits including the National Center for Women in Technology (NCWIT). She was previously an independent director for Cloudera and currently serves on the board for Zurn Water Solutions. Ms. Schooler earned a BS in ceramic science and engineering from Penn State University.

About Arm

Arm technology is defining the future of computing. Our energy-efficient processor designs and software platforms have enabled advanced computing in more than 240 billion chips and our technologies securely power products from the sensor to the smartphone and the supercomputer. Together with 1,000+ technology partners, we are enabling artificial intelligence to work everywhere, and in cybersecurity, we are delivering the foundation for trust in the digital world – from chip to cloud. The future is being built on Arm.

All information is provided "as is" and without warranty or representation. This document may be shared freely, attributed and unmodified. Arm is a registered trademark of Arm Limited (or its subsidiaries). All brands or product names are the property of their respective holders. © 1995-2022 Arm Group.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221130005040/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma’s Relfydess™ (relabotulinumtoxinA) Receives Approval in China for Frown Lines23.10.2026 07:00:00 CEST | Press release

The Chinese National Medical Products Administration (NMPA) has approved Relfydess™, the first and only ready-to-use liquid neuromodulator designed with PEARL™ Technology, for the temporary improvement of moderate-to-severe glabellar lines (frown lines) in adults1,2 The approval is based on phase III results from a local clinical trial conducted in China as well as global READY clinical trials, with local results reinforcing that Relfydess delivers significant improvements in frown lines, with a fast onset of action as early as day one, and sustained results for up to six months in some patients3-7 This approval underscores Galderma’s continued leadership in the Asia-Pacific region and further expands the global reach of Relfydess, which is already authorized in more than 35 markets worldwide Galderma (SIX: GALD) today announced that the Chinese NMPA has approved Relfydess for the temporary improvement of moderate-to-severe frown lines in adults, marking a significant expansion of the

Andersen Consulting får ny samarbejdspartner i Usbekistan22.10.2026 21:34:00 CEST | Pressemeddelelse

Andersen Consulting udvider sine kompetencer inden for cybersikkerhed og forretningstransformation gennem en samarbejdsaftale med Algoruni, et konsulentfirma med base i Usbekistan. Algoruni rådgiver organisationer om at opbygge cyberrobusthed og håndtere bredere prioriteter inden for ledelse, regulering og bæredygtighed. Virksomheden har base i Tasjkent og tilbyder tjenester inden for cybersikkerhedsstrategi og databeskyttelse, virksomhedsledelse og driftsforbedringer samt ESG-strategi og -rapportering. Fokus er på praktiske løsninger, der er tilpasset den enkelte kundes situation. "Enhver organisation står over for en unik kombination af risici og muligheder. Derfor mener vi, at effektive løsninger skal tage udgangspunkt i virksomhedens konkrete situation," udtalte Alisher Zaynutdinov, administrerende direktør for Algoruni. "Som samarbejdsvirksomhed med Andersen Consulting kan vi kombinere denne tilgang med et bredere netværk af internationale ressourcer og perspektiver, så vi får nye

Andersen Global udvider sine juridiske kompetencer i Argentina gennem samarbejde med MHR22.10.2026 20:20:00 CEST | Pressemeddelelse

Andersen Global styrker sine juridiske kompetencer i Argentina gennem en samarbejdsaftale med Martínez de Hoz & Rueda (MHR) efter integrationen af teamet fra MBP Partners i firmaet. MBP Partners var tidligere et samarbejdsfirma i Andersen Global og arbejdede sammen med organisationens medlemsfirmaer og samarbejdsfirmaer for at bistå klienter med både lokale og internationale forhold. Med integrationen af MBP Partners viderefører den nye samarbejdsaftale mellem Andersen Global og MHR det eksisterende samarbejde og styrker samtidig Andersen Globals juridiske kompetencer i Argentina. MHR er et fullservice advokatfirma, der rådgiver klienter inden for olie og gas, selskabsretlige og finansielle forhold, energi, minedrift, fintech, infrastruktur, teknologi og andre centrale sektorer. Firmaet bistår danske og internationale virksomheder, finansielle institutioner, investeringsfonde, fintechvirksomheder og andre organisationer med komplekse transaktioner, regulatoriske spørgsmål og strategisk

Mundipharma Announces Further Phase III ReSPECT Results Presented as a Late-Breaking Oral Presentation at IDWeek 202622.10.2026 19:03:00 CEST | Press release

For Trade and Medical Media Only Today Mundipharma announced additional results from the global Phase III ReSPECT clinical trial evaluating REZZAYO®(rezafungin acetate) for prophylaxis of invasive fungal diseases (IFDs) in adult patients undergoing allogeneic haematopoietic stem cell transplantation (allo-HSCT). The Phase III findings were presented today as a late-breaking oral presentation at IDWeek 2026. The presentation provides additional detail following the top line ReSPECT results announced in April 2026, including further endpoint analyses, the components contributing to fungal-free survival (FFS), pre-specified sensitivity analyses and detailed safety outcomes. The additional analyses were consistent with the previously announced topline findings. ReSPECT was a global, multicentre, randomised, double-blind Phase III study in which 402 patients were randomised to rezafungin and 200 to the standard antimicrobial regimen. As previously announced, the study met its primary endpoi

Tigo Energy Improves Installer Choice via Fronius Compatibility with TS4 Product Line22.10.2026 18:02:00 CEST | Press release

Compatibility between Tigo MLPE and multiple Fronius inverter families gives solar installers worldwide greater flexibility to design high-quality systems with the features customers want. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy software solutions, today announced a manufacturer declaration of compatibility from Fronius International GmbH, documenting compatibility between Tigo Flex MLPE products and multiple Fronius inverter families. The letter covers Tigo TS4-A-F, TS4-A-2F, TS4-A-O, and TS4-X-O products and the Fronius Primo GEN24, Primo GEN24 208-240, Symo GEN24, Verto, Tauro, and Tauro ECO inverter families, when configured according to the requirements specified by Fronius and Tigo. Building on established compatibility in Europe, the declaration extends manufacturer-confirmed compatibility to markets worldwide, including the United States and Canada, giving solar professionals greater flexibility to design high-q

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye